

Newsletter

Lund 13 AUG 2021

Scandinavian ChemoTech participates in the European Oncology Convention 2021

Mohan Frick will participate and present at the European Oncology Convention 2021 that is held in Birmingham, UK on 15-16 September.

The Oncology Convention is dedicated to advancing clinical oncology and life-saving research. The show provides the perfect platform to source the latest innovations and CPD accredited education in preventing, diagnosing, treating, and caring for breast, colorectal, lung and prostate cancer.

A CPD accredited seminar programme will run alongside the exhibition, hosted by the leading clinicians and researchers in worldwide cancer prevention, diagnosis, treatment and care. The programme features sessions from the likes of Philips, University College London, Prostate Cancer UK, Breast Cancer UK, The Royal Marsden NHS Foundation Trust and The Christie NHS Foundation Trust.

For further information please contact:

Mohan Frick, CEO

+46 (0)10-218 93 00

info@chemotech.se

Certified Adviser: Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00,

E-mail: certifiedadviser@penser.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se